Development and Testing of an Alternative Responder Definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2023 Mar 17

PMID 36931685

Authors

Samantha Wratten

Linda Abetz-Webb

Ethan Arenson

Pip Griffiths

Simon Bowman

Wolfgang Hueber

Briana Ndife

Daniel Kuessner

Pushpendra Goswami

Affiliations

Soon will be listed here.

Abstract

Objectives: Dryness, fatigue and joint/muscle pain are typically assessed in Sjögren's trials using European Alliance of Associations for Rheumatology Sjögren's Syndrome Patient Reported Index (ESSPRI). A Patient Acceptable Symptom State of <5 and a Minimal Clinically Important Improvement (MCII)/responder definition (RD) of ≥1 point or 15% on ESSPRI have previously been defined. This study explored alternative RDs to better discriminate between active treatment and placebo in trials.

Methods: Anchor-based and distribution-based methods were used to derive RD thresholds in blinded phase IIb trial data (N=190) and confirm these in blinded data pooled from three early phase II trials (N=126). The populations consisted of individuals with moderate-to-severe systemic primary Sjögren's. Anchors were prioritised by ESSPRI correlations and used in similar conditions. Triangulated estimates were discussed with experts (N=3). The revised RD was compared with the original using unblinded data to assess placebo and treatment responder rates.

Results: Patients were predominantly female (>90%), white (90%), with mean age of 50 years. Receiver operating characteristic estimates supported an MCII threshold of 1.5-1.6 in the phase II data, whereas correlation-weighted mean change estimates supported a low/minimal symptom severity threshold of ≥2. A low/minimal symptom severity of ≤3 showed the greatest sensitivity/specificity balance. Analyses in the pooled data supported these thresholds (MCII: 1.5-2.1; low/minimal symptom severity: 2.7-3.7). Unblinded analyses confirmed the revised RD reduced placebo rates.

Conclusions: Completing a trial with an improvement of ≥1.5 points compared with baseline and an ESSPRI score of ≤3 points is a relevant RD for moderate-to-severe systemic Sjögren's and reduces placebo rates.

References

Alunno A, Bartoloni E, Valentini V, La Paglia G, Valentini E, Leone M . Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. Clin Exp Rheumatol. 2018; 36 Suppl 112(3):210-214. View

Bowman S . Patient-reported outcomes including fatigue in primary Sjögren's syndrome. Rheum Dis Clin North Am. 2008; 34(4):949-62, ix. DOI: 10.1016/j.rdc.2008.08.010. View

Norman G, Sloan J, Wyrwich K . The truly remarkable universality of half a standard deviation: confirmation through another look. Expert Rev Pharmacoecon Outcomes Res. 2009; 4(5):581-5. DOI: 10.1586/14737167.4.5.581. View

Seror R, Theander E, Brun J, Ramos-Casals M, Valim V, Dorner T . Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2014; 74(5):859-66. DOI: 10.1136/annrheumdis-2013-204615. View

Kocer B, Tezcan M, Batur H, Haznedaroglu S, Goker B, Irkec C . Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations. Brain Behav. 2016; 6(12):e00586. PMC: 5167008. DOI: 10.1002/brb3.586. View

Bowman S, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T . Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2021; 399(10320):161-171. DOI: 10.1016/S0140-6736(21)02251-0. View

Milic V, Grujic M, Barisic J, Marinkovic-Eric J, Duisin D, Cirkovic A . Personality, depression and anxiety in primary Sjogren's syndrome - Association with sociodemographic factors and comorbidity. PLoS One. 2019; 14(1):e0210466. PMC: 6336324. DOI: 10.1371/journal.pone.0210466. View

Cooper C, Wratten S, Williams-Hall R, Bookman A, Ndife B, Hueber W . Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's. Rheumatol Ther. 2022; 9(6):1499-1515. PMC: 9561458. DOI: 10.1007/s40744-022-00487-0. View

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View

10.

Lackner A, Ficjan A, Stradner M, Hermann J, Unger J, Stamm T . It's more than dryness and fatigue: The patient perspective on health-related quality of life in Primary Sjögren's Syndrome - A qualitative study. PLoS One. 2017; 12(2):e0172056. PMC: 5300216. DOI: 10.1371/journal.pone.0172056. View

11.

Revicki D, Hays R, Cella D, Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008; 61(2):102-9. DOI: 10.1016/j.jclinepi.2007.03.012. View

12.

Mandrekar J . Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-6. DOI: 10.1097/JTO.0b013e3181ec173d. View

13.

Segal B, Bowman S, Fox P, Vivino F, Murukutla N, Brodscholl J . Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes. 2009; 7:46. PMC: 2693523. DOI: 10.1186/1477-7525-7-46. View

14.

Froud R, Abel G . Using ROC curves to choose minimally important change thresholds when sensitivity and specificity are valued equally: the forgotten lesson of pythagoras. theoretical considerations and an example application of change in health status. PLoS One. 2014; 9(12):e114468. PMC: 4256421. DOI: 10.1371/journal.pone.0114468. View

15.

Arends S, de Wolff L, van Nimwegen J, Verstappen G, Vehof J, Bombardieri M . Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2024; 3(8):e553-e562. DOI: 10.1016/S2665-9913(21)00122-3. View

16.

Katz N, Paillard F, Ekman E . Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. J Orthop Surg Res. 2015; 10:24. PMC: 4327973. DOI: 10.1186/s13018-014-0144-x. View

17.

Wyrwich K, Tierney W, Wolinsky F . Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999; 52(9):861-73. DOI: 10.1016/s0895-4356(99)00071-2. View

18.

Meiners P, Arends S, Brouwer E, Spijkervet F, Vissink A, Bootsma H . Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis. 2012; 71(8):1297-302. DOI: 10.1136/annrheumdis-2011-200460. View

19.

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

20.

de Wolff L, Vissink A, van Nimwegen J, van Zuiden G, Mossel E, Olie L . Patient Acceptable Symptom State (PASS) in patients with primary Sjögren's syndrome in daily clinical practice. Clin Exp Rheumatol. 2022; 40(12):2303-2309. DOI: 10.55563/clinexprheumatol/mnqiy9. View